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Abstract: Objective: Restoring intracellular cGMP and inducing NO-synthesis attenuates ischemia-
associated early pulmonary allograft dysfunction. Phosphodiesterase-5 (PDE), predominantly expressed
in lung tissue, plays a pivotal role in modulating the cGMP/NO-synthase pathway in endothelial and
epithelial cells. In this study, we evaluate the effect of employing sildenafil (Viagra®), a specific inhibitor
of PDE-5, to counteract ischemia/reperfusion (I/R) injury in a single lung transplantation model of
extended ischemia. Methods: Donor animals (weight matched outbred pigs, 28-35 kg) in the treatment
group (I) (n = 5) were injected with 0.7 mg sildenafil/kg into the pulmonary artery (PA) prior to inflow
occlusion. For perfusion, Perfadex®, containing 0.7 mg sildenafil/l was used, and the graft stored at 1
°C in the perfusion solution. After 24 h ischemia, unilateral left lung transplantation was performed.
Starting at reperfusion, group I received continuous sildenafil (0.7 mg sildenafil/kg), over 6 h. Except
for the sildenafil application, the control group (II) (n = 4) was treated identically (PGE1 was injected
into the PA). One hour after reperfusion, the right main bronchus (MB) and right PA were occluded.
Over the next 5 h, cardiopulmonary parameters (systemic aterial, PA, central venous, left atrial pressure,
pCO2, pO2) were measured, including extravascular lung water (EVLW). Thiobarbituric acid-reactive
substance assay (TBARS) and myeloperoxidase (MPO) analysis from lung tissue were run. Results: All
recipients of group I survived the 6-h reperfusion period; in contrast, all control animals died within
1-2 h after occlusion of the right side. In comparison to a marked rise in pulmonary vascular resistance
(PVR) in group II (>1000 dyne s cm−5), PVR in group I remained stable, moderately elevated from
baseline (baseline: 150-180 dyne s cm−5 vs endpoint: 1000 dyne s cm−5). EVLW in group I did not
increase during reperfusion (baseline: 6.75 ± 1.4 mg/kg vs endpoint: 6.7 ± 1.0 mg/kg), in contrast
to group II, where pulmonary edema at 2-h reperfusion preceded terminal graft failure (group I: 9.7
± 0.1 mg/kg vs group II: 6.48 ± 1.8 mg/kg). Tissue reactive free radicals at endpoint measurement
in group I did not differ significantly from native tissue. Yet, when compared to specimen taken from
group II at time of terminal graft failure, a significant increase in free radicals was noted (group I: 13.8
± 1.6 pmol/g vs group II: 18.5 ± 3.0 pmol/g, p < 0.05). Conclusion: Sildenafil treatment prevents
terminal early graft failure, allowing lung transplantation after 24-h ischemia time. Reperfusion edema
was strikingly diminished, preserving pulmonary structural and functional integrity while prolonging graft
ischemia time. Employing the established PDE-5 inhibitor sildenafil during lung perfusion, storage, and
implantation, ischemic tolerance may be extended and early graft function improved
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Abstract
Objective: Restoring intracellular cGMP and inducing NO-synthesis attenuates ischemia-associated early pulmonary allograft dysfunction.
Phosphodiesterase-5 (PDE), predominantly expressed in lung tissue, plays a pivotal role in modulating the cGMP/NO-synthase pathway in
endothelial and epithelial cells. In this study, we evaluate the effect of employing sildenafil (Viagra1), a specific inhibitor of PDE-5, to counteract
ischemia/reperfusion (I/R) injury in a single lung transplantation model of extended ischemia.Methods: Donor animals (weight matched outbred
pigs, 28—35 kg) in the treatment group (I) (n = 5) were injected with 0.7 mg sildenafil/kg into the pulmonary artery (PA) prior to inflow occlusion.
For perfusion, Perfadex1, containing 0.7 mg sildenafil/l was used, and the graft stored at 1 8C in the perfusion solution. After 24 h ischemia,
unilateral left lung transplantation was performed. Starting at reperfusion, group I received continuous sildenafil (0.7 mg sildenafil/kg), over 6 h.
Except for the sildenafil application, the control group (II) (n = 4) was treated identically (PGE1 was injected into the PA). One hour after
reperfusion, the right main bronchus (MB) and right PA were occluded. Over the next 5 h, cardiopulmonary parameters (systemic aterial, PA,
central venous, left atrial pressure, pCO2, pO2) were measured, including extravascular lung water (EVLW). Thiobarbituric acid-reactive
substance assay (TBARS) and myeloperoxidase (MPO) analysis from lung tissue were run. Results: All recipients of group I survived the 6-h
reperfusion period; in contrast, all control animals died within 1—2 h after occlusion of the right side. In comparison to amarked rise in pulmonary
vascular resistance (PVR) in group II (>1000 dyne s cm5), PVR in group I remained stable, moderately elevated from baseline (baseline: 150—
180 dyne s cm5 vs endpoint: 1000 dyne s cm5). EVLW in group I did not increase during reperfusion (baseline: 6.75  1.4 mg/kg vs endpoint:
6.7  1.0 mg/kg), in contrast to group II, where pulmonary edema at 2-h reperfusion preceded terminal graft failure (group I: 9.7  0.1 mg/kg vs
group II: 6.48  1.8 mg/kg). Tissue reactive free radicals at endpoint measurement in group I did not differ significantly from native tissue. Yet,
when compared to specimen taken from group II at time of terminal graft failure, a significant increase in free radicals was noted (group I:
13.8  1.6 pmol/g vs group II: 18.5  3.0 pmol/g, p < 0.05). Conclusion: Sildenafil treatment prevents terminal early graft failure, allowing lung
transplantation after 24-h ischemia time. Reperfusion edema was strikingly diminished, preserving pulmonary structural and functional integrity
while prolonging graft ischemia time. Employing the established PDE-5 inhibitor sildenafil during lung perfusion, storage, and implantation,
ischemic tolerance may be extended and early graft function improved.
# 2005 Elsevier B.V. All rights reserved.
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1. Introduction
Clinical lung transplantation is limited by the scarcity of
suitable grafts and low organ-specific ischemic tolerance.
Extensive ischemia/reperfusion (I/R) injury may lead to early
graft dysfunction following pulmonary transplantation in ca.
15% of recipients. The hallmarks of I/R injury in the lung are
an increase of vascular permeability, permeating pulmonary
edema, endothelial desquamation, and neutrophil seques-
tration. The course of I/R injury can be attenuated by
induction of the NO- and prostaglandin-synthesis pathways,
where cAMP and cGMP function as second messengers.
Through hydrolysis of these cyclic nucleotides, phospho-
diesterases (PDE) play a pivotal role in cGMP- and cAMP-
mediated signal transduction. Varying in terms of tissue and
substrate specificity, 11 families of phosphodiesterases exist
[1], with high concentrations of PDE-4 and -5 in pulmonary
parenchyma [2,3]. By metabolizing cAMP, PDE-4 modulates
prostaglandin synthesis. Recently, we have preserved lung
allograft function in a model of prolonged ischemia by
employing a novel PDE-4 inhibitor (PDI747) [4].
Phosphodiesterase-5 has been identified as the primary
cGMP-hydrolyzing enzyme in human corpus cavernosal and
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pulmonary tissue [5]. High intracellular concentrations of
cGMP,which are converted fromGTP by NO-activated guanyl
cyclases, initiate protein phosphorylation, with ensuing
bronchial and vascular dilation [5]. The importance of the
cGMP/NO-synthesis-pathways in targeting I/R injury has
been demonstrated by our group: simultaneous admini-
stration of 8-Br-cGMP (second messenger of NO) and
tetrahydrobiopterin (coenzyme of NO-synthase) preserved
pulmonary graft function in the pig after 30-h ischemia [6].
Given the predominant distribution of PDE-5 in the lung,
and on the basis of the crucial role of cGMP in maintaining
cellular functionality during reperfusion after extended
ischemia, we investigated the influence of selective PDE-5
inhibition with sildenafil (Viagra1) on graft survival after
extended ischemia.
2. Materials and methods
2.1. Animals and procedures
Nine weight-matched pairs of outbred pigs, randomized
into control and study group, served as donors and
recipients. Harvest and left lung transplantations were
performed as previously reported [4,6]. Lungs were flushed
with 1.0 l of LPD solution (Perfadex, Vitrolife AB, Kungs-
backa, Sweden) and stored at a temperature of 1 8C for 24 h.
One hour after reperfusion, the right contralateral lung was
excluded from perfusion and ventilation. All animals
received humane care in compliance with the European
Convention on Animal Care. The protocol was approved by
the local animals study committee.
2.2. Study groups
Two groups were studied. In group I (n = 5), sildenafil
(0.7 mg/kg, Pfizer, Zurich, Switzerland) was injected into the
pulmonary artery (PA) before inflow occlusion. In addition,
LPD containing 0.7 mg sildenafil/l was used as flush solution.
During backtable preparation, the isolated left lung was
perfused retrograde with 500 ml LPD containing 0.7 mg/l
sildenafil. Furthermore, recipients of these grafts received
continuous i.v. infusion with 0.7 mg/kg sildenafil over 5 h,
starting at reperfusion. In group II (n = 4), 8 mg/kg prosta-
glandin E1 (PGE1) (Prostin VR Pediatric; The Upjohn
Company, Kalamazoo, MI, USA) was injected into the PA
before flushing, as in clinical use. For in vivo and backtable
perfusion, LPD was employed. Preservation time of groups I
and II donor lungs was 24 h.
2.3. Assessment
One hour after reperfusion of the transplanted lung, the
right PA (including the branch to the upper lobe) and the right
main bronchus were ligated to assess isolated allograft
function for the following 5 h after reperfusion. During the
assessment period, anaesthesia was maintained with Iso-
flurane 1.5%. FiO2 was 1.0 tidal volume 5.5 l at a respiratory
rate of 20 min1 and a PEEP of 5 mm H2O. Systemic arterial,
PA, central venous, and left atrial pressure were recorded
continuously. Arterial and mixed venous blood was collected
for gas analysis every 60 min. Upper lobe allograft samples
were collected and snap frozen at 80 8C in liquid nitrogen
for tissue MPO and TBARS assay. Time of tissue harvest was at
time of spontaneous death (2—3 h after reperfusion for the
control animals) and at 5 h after reperfusion for the treated
recipients (endpoint). All values are given as mean  stan-
standard deviation of the mean (SD).
2.4. Extravascular lung water
Extravascular lung water as direct assessment of
reperfusion edema was measured as previously described
[6]. A fiberoptic catheter (System Cold Z-021, Pulsion,
Munich, Germany) was advanced via the external carotid
artery into the descending aorta. The indicator bolus
consisted of two components: indocyanine green served
as an intravascular marker and ice cold 5% glucose as a
thermal intra- and extravascular indicator. The bolus was
injected via the external jugular vein with a temperature-
controlled injector. The dilution curves for dye and
temperature were recorded simultaneously in the descend-
ing aorta with the thermistor-tipped fiberoptic catheter.
Thoracic intravascular and extravascular fluid volumes were
determined based on the measurement of the mean transit
times for thermal and dye indicators and of the decay time
volumes calculated from the indicator dilution curves. The
lung water computer (System Cold Z-021, Pulsion) deter-
mined the mean transit time for the thermal indicator and
for the dye indicator and calculated total thermal volume
(ITTV), intrathoracic blood volume (ITBV), and extravas-
cular thermal volume (ETV). The extravascular thermal
volume (ETV) was calculated as follows: ETV = ITTV  ITBV.
All measurements were made in triplicate. The mean value
was used for analysis.
2.5. Myeloperoxidase assay
Donor and recipient lung samples were frozen immedi-
ately and stored at80 8C until assessment. MPO levels were
measured using a myeloperoxidase assay kit (Cytostore,
Calgary, Canada). Enzyme activity was expressed as change
in optical density units per milligram of tissue protein per
minute (DOD/(mg min)).
2.6. TBARS assay
Thiobarbituric acid-reactive substance (TBARS) levels in
lung tissue were measured with the NWLSS kit from
Northwest (Northwest Life Sciences Specialities, Vancouver,
Canada) following the company protocol. Briefly a 10% (w/v)
was prepared and TBARS levels were determined by
reference to a standard curve of 1,1,3,3-tetramethoxypro-
pane and the results were expressed as nanomoles of
malondialdehyde (MDA) per gram of wet lung.
2.7. Hemodynamic parameters and gas exchange
Systemic arterial, PA, central venous, and left atrial
pressure were recorded continuously with a hemodynamic
monitor system (Hellige, Freiburg, Germany). Measurement
of cardiac output was necessary for the lung water
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assessment (System Cold Z-021, Pulsion). Pulmonary vascular
resistance was calculated in CGS units according Poiseuille’s
law. Arterial and mixed venous blood was collected for gas
analysis every 60 min.
3. Results
No differences between groups were noted in donor
weight (group I: 32.4  3.1 kg vs group II: 30.8  2.2 kg),
recipient weight (group I: 34.2  3.9 kg vs group II: 34.5 
2.8) and total preservation time (group I: 1557  35 min vs
group II: 1526  23 min).
All five recipients from group I survived until the end of the
experiment (1 h of bilateral perfusion, followed by 5 h of
isolated graft ventilation/perfusion). In contrast, all four
recipients of group II died within 1—2 h after occlusion of the
right side, with signs of severe pulmonary edema and acute
right heart failure.
Extravascular lung water in group II was markedly
increased by 1 h following occlusion of the right side
(9.7  0.1 mg/kg), in comparison to the grafts in group I
(6.48  1.8 mg/kg). Since all recipients in group II died
between 2 and 3 h after reperfusion (1—2 h after occlusion of
the right side), continuous EVLW measurements over 360 min
could only be obtained for group I. During the entire
observation period, EVLW remained stable in group I without
a significant increase during 5 h of isolated allograft
perfusion/ventilation (6.75  1.4 mg/kg vs 6.7  1.0 mg/
kg) (Fig. 1).
Neutrophil migration, based on assessing myeloperox-
idase activity in the tissue, did not differ significantly
between the two groups (group I at endpoint: 3.6  0.7 U/mg
vs group II at time of terminal graft failure: 3.7  1.4 U/mg;
native tissue: 0.6  1.5 U/mg). However, free radical tissue
damage expressed as MDA concentration per gram wet lung
was significantly lower in group I compared to group II (group
I at endpoint: 13.8  1.6 mM vs group II at time of terminal
graft failure: 18.5  3.0 mM, p < 0.05; native tissue: 12.4 
0.9 mM) (Fig. 2).
In the treated recipients, arterial oxygenation deterio-
rated moderately following occlusion of the right side, but
remained stable throughout the observation period (base-
line: 41.6  20.1 kPa vs endpoint: 16.8  2.1 kPa). Pulmon-
ary vascular resistance (PVR) in group II increased markedly
within 1 h after exclusion of the right side, and all animals
died within the following 1—2 h with values over
1000 dyne s cm5. In contrast, all recipients from group I
survived a 6-h reperfusion period, displaying a moderately
increased PVR (400—500 dyne s cm5) at endpoint measure-
ment (Fig. 3).
4. Discussion
Sildenafil application during pig lung allograft procure-
ment and reperfusion attenuated I/R injury and abolished
fatal early graft dysfunction after 24-h preservation time.
Employing the novel and specific PDE-5 inhibitor sildenafil
prevented reperfusion-associated pulmonary edema, stabi-
lized recipient pulmonary vascular resistance, and signifi-
cantly reduced free radical tissue damage. This is the first
study to report on the successful pharmacological precondi-
tioning (PC) with sildenafil of grafts undergoing extended
ischemia in a large animal lung transplantation model.
Extending the clinical potential of sildenafil, recent
studies investigate its therapeutic significance in treating
pulmonary arterial hypertension (PAH) and in attenuating I/R
injury in models of tissue preservation [5]. Accumulating
evidence from various mechanistic studies indicate a multi-
factorial mode of action, where sildenafil (i) induces iNOS
expression [7], (ii) activates protein kinase C [8], (iii) inhibits
the catalytic hydrolysis of cGMP [9], and (iv) opens
mitochondrial KATP channels [10].
Brief episodes of ischemia [11], or administration of
certain pharmacological agents, i.e., adenosine, bradykinin,
opioids, and free radicals [12], have been shown to reduce
tissue necrosis and preserve myocardial contractile function
[5]. The vasodilation induced by sildenafil can mediate this
effect of ischemic preconditioning: release of adenosine/
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Fig. 1. Extravascular lung water (EVLW) measurements for both groups during observation time. Timepoints: 0 min (at reperfusion), 60 min (after occlusion of the
right side), and 70—360 min (measurements every 60 min). Group I (treated) remained stable without significant increase during the whole observation period
(baseline: 6.75  1.4 mg/kg vs endpoint: 6.7  1.0 mg/kg). In group II, grafts were markedly increased by 1 h following occlusion of the right side (9.7  0.1 mg/kg),
in comparison to the grafts in group I (6.48  1.8 mg/kg). Since all recipients in group II died between 2 and 3 h after reperfusion (1—2 h after occlusion of the right
side), continuous EVLW measurements over 360 min could only be obtained for group I.
bradykinin triggers a signaling cascade, leading to the
phosphorylation of nitric oxide synthases (eNOS/iNOS), with
subsequent release of NO. Nitric-oxide-induced guanyl-
cyclase-activation eventually raises cGMP levels, in turn
activating protein kinase G (PKG), which can open mitoKATP
channels. The opening of mitoKATP channels will in part
recompensate the electrochemical gradient for ATP synthesis
and Ca2+ transport, thus maintaining intracellular energy
status [5].
In our study, sildenafil has been used for direct organ-
specific preconditioning and, during reperfusion, systemi-
cally. To appropriately evaluate the influence of this novel
PDE-5-inhibitor on early graft function, both the local and the
systemic effect have to be taken into consideration. Given
the pivotal role of phosphodiesterases in modifying cellular
cGMP concentration, the predominance of PDE-5 in pulmon-
ary parenchyma [3] supports the rationale of targeting this
enzyme with a specific inhibitor. When sildenafil is injected
into the pulmonary circulation, it affects both endothelial
and epithelial cells. First, sildenafil has a central role as a
competitive substrate analogon of cGMP for the catalytic
epitope of PDE-5. Inhibiting enzymatic hydrolysis of cGMP
preserves high intracellular levels of this cyclic nucleotide,
which are pivotal in mediating further tissue protection.
As a direct hemodynamic consequence, an increasing cGMP
pool triggers protein kinase G-induced protein phospho-
rylation, lowering intracellular Ca2+ concentrations, leading
to vascular dilation. Second, in a mouse heart I/R model,
sildenafil administration induced a transient increase in
intra-organ eNOS and iNOS mRNA expression, resulting in a
significant rise of cardiac NO-synthase protein levels after
24 h [7]. Third, systemically, sildenafil lowers pulmonary
artery systolic pressure and significantly increases cardiac
output, which is clinically being exploited in treating
pulmonary arterial hypertension [13].
We have observed a significant attenuation of free radical
tissue damage in the sildenafil-treated group. Interestingly,
this effect has been noted in another in vivo study, where
doxorubicin-associated cardiotoxicity in mice, mediated
through the generation of reactive oxygen species, could
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Fig. 2. Lipid peroxidation. Thiobarbituric acid reactive substance (TBARS) levels in the graft as measurement for lipid peroxidation 6 h after reperfusion (group I) and
2—3 h after reperfusion at terminal graft failure (group II). Specimen from treated recipients (group I) showed significantly lower free radical damage than untreated
animals (group I: 13.8  1.6 mM vs group II: 18.5  3.0 mM, p < 0.05; native tissue: 12.4  0.9 mM).
Fig. 3. Pulmonary vascular resistance (PVR) measurements for both groups during observation time. Timepoints: 0 min (at reperfusion), 60 min (after occlusion of the
right side), and 70—360 min (measurements every 60 min). PVR in group II increased markedly within 1 h after exclusion of the right side, and all animals died within
the following 1—2 h with values over 1000 dyne s cm5. All recipients from group I survived the 6-h reperfusion period, displaying a moderately increased PVR (400—
500 dyne s cm5) at endpoint measurement.
be prevented by sildenafil application. In this model,
employing the same dose of 0.7 mg/kg sildenafil three times
over the course of eight weeks, cardiomyocyte apoptosis was
inhibited, preserving myocardial histomorphology and left
ventricular function. It has been shown that this effect
depends on NO-synthase and the opening of mitoKATP
channels [14]. These results may indicate a broader
therapeutical horizon for employing sildenafil in clinical
lung transplantation. In addition to its efficacy in preventing
early graft dysfunction, an intermediate, antiapoptotic
effect may be postulated. So far, this has only been observed
in cardiomyocytes [14,15], so further studies are needed to
assess this effect on long-term graft endothelial and
epithelial cell integrity.
Monitoring of arterial oxygenation in treated recipients in
this model has been shown in the past to reflect the course of
graft performance not adequately [6]. A large intraindivi-
dual variability and the sensitivity of the porcine cardio-
pulmonary circulation to surgical manipulation may in part
obscure the clinical picture. In spite of the fact that paO2 is
often used as a critical parameter to assess lung function in
other studies, the lung water computer employed in this
model allows us a precise and extensive assessment of the
dynamic changes of pulmonary edema following implanta-
tion. The pronounced effect on reducing lungwater has been
recently described for another specific PDE-5 inhibitor
(E4201), in near term fetal lambs. Direct infusion of E4201
showed a NOS-independent decrease of net liquid produc-
tion [16].
Taken together, employing the novel-specific PDE-5
inhibitor sildenafil for graft perfusion, storage and during
the early reperfusion period preserves pulmonary functional
and structural integrity, and enables lung allograft trans-
plantation after an extended ischemic period of 24 h. This
pharmacologically safe and well-established PDE-5 inhibitor
may find a place for attenuating early graft dysfunction in
clinical lung transplantation in the future.
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Appendix A. Conference discussion
Dr R. Schmid (Berne, Switzerland): I know the model very well. First of all,
why did you put the prostaglandin in the flush solution in the control group and
not in the treatment group?
Dr Korom: Well, we did not put it in the flush solution. We injected it into
the pulmonary artery.
Dr Schmid: It was not clear, because you wrote Perfadex plus
prostaglandin.
Dr Korom: I apologize if this was not made clear.
Dr Schmid: So you compared prostaglandin injection versus . . ..
Dr Korom: Sildenafil injection.
Dr Schmid: Did you do that because the animals in the control group did not
survive?
Dr Korom: No. We performed the regular explantation, and before inflow
occlusion, prostaglandin was injected into the PA.
Dr Schmid: But you didn’t do that in the other group.
Dr Korom: Not the PGE. We used sildenafil instead.
Dr Schmid: And the second thing is the endpoint assessment. When the
animals die after 3 h and you assess neutrophil migration in one group, with the
MPO assay, in one group you measure it 3 h after refusion, and in the other
group at sacrifice. You cannot compare the data at all because the reperfusion
is 4 h longer.
Dr Korom: It’s hard to compare. However, we had these dying animals and
we were trying to get some data in that situation. So it is a problem, yes.
Dr Schmid: But this is not valuable data. The second thing is, did you
measure extracorporeal lung water? This can be done repetitively, and
when the animal is dying, you have some data you can compare at a specific
time point.
Dr Korom: I did show it. It was the second slide, but we can go over it
later on.
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Dr N. Pizanis (Essen, Germany): What was the direct problem? Why did
all of your control animals die within 3 h? Was it reperfusion edema, or what
was it?
Dr Korom: Graft failure due to pulmonary edema and finally cardiac
arrest. We have had control animals for 30 h of ischemia surviving in our
laboratory basically with the same settings, with the same surgeons. So this is
just an inter-animal difference we were observing. But it was striking that
from the same batch of animals, all the sildenafil-treated showed no problems.
Dr Pizanis: Did the problem start after clamping of the right pulmonary
artery? We have this model, too, and I know that this is a tricky moment.
Dr Korom: Right, this is a tricky moment. But usually in the treated group,
they all leveled out, but that’s when conditions with the control animals
started to deteriorate.
Dr Pizanis: Did you have hemodynamic data from a Swan-Ganz catheter?
Dr Korom: Yes.
Dr Pizanis: And did you react with catecholamines or anything in order to
counteract . . .
Dr Korom: We tried to save them, but it was no use.
Dr D. Van Raemdonck (Leuven, Belgium): We have also used this model
and we know that it’s not an easy model, because after clamping of the right
pulmonary artery, you force the whole cardiac output through the transplanted
postischemic lung. We have found that by modifying the arterial anastomosis
from an end-to-end anastomosis to a more side-to-side anastomosis with a
patch technique this wasmuch better tolerated by the animals. So my question
to you is, what type of arterial anastomosis did you use, and have you used the
same technique in both groups?
Dr Korom: Yes. It’s end-to-end and the same in both groups for the artery.
Dr S. Aharinejad (Vienna, Austria): We were students of your group when
we came to Zurich . . .
Dr Korom: Well, you were guests.
Dr Aharinejad: We were guests, and we thank you all for teaching it. It’s
interesting looking at this laboratory. We went back to Vienna. We
transplanted the rat model, Fisher-Lewis, and we did 40 transplantations.
All the rats died. We had several problems. We managed to overcome the
problems, technical problems, which were our fault, and all the animals had
edema, and according to the protocol utilized in your laboratory, in your
institution, the animals were not supposed to receive PGE, and then we started
prostaglandin and the animals are doing perfect.
Dr Korom: This is a very interesting observation in another species. We
have never seen these problems with the rats. I’m not in Zurich anymore, but
maybe my co-workers should come to Vienna and have a look.
Dr M. Kamler (Essen, Germany): I just want to come back to the technique
of the anastomosis. Maybe you should try to do pressure gradients before and
after the anastomosis, because we found the same problem when we did the
pilot experiments.
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